Sharpe Robert W, Bethel Kelly J
Department of Pathology, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA.
Hematol Oncol Clin North Am. 2006 Oct;20(5):1023-49. doi: 10.1016/j.hoc.2006.06.010.
The pathology of HCL has been reviewed with a focus on the diagnostic hematopathology of this rare, but fascinating, disease. The discrimination of HCL from other B-cell lymphoproliferations, particularly HCL-V and SMZL, has been emphasized. The unique responsiveness of HCL to 2-CdA and other chemotherapeutic agents makes this distinction critical. Fortunately, HCL has consistent cytologic, histologic, cytochemical, and immunologic features that make classification reliable and reproducible. Less straightforward is the differential diagnosis of SMZL and HCL-V, problematic because of the rarity of both disorders, lack of discriminating evidence-based criteria, and perhaps a biologic kinship between these two disorders that share many clinical and pathologic features. Fortunately, this is not a clinically critical distinction.
本文回顾了毛细胞白血病(HCL)的病理学,重点关注这种罕见但引人入胜的疾病的诊断血液病理学。文中强调了HCL与其他B细胞淋巴增殖性疾病的鉴别,特别是与变异型毛细胞白血病(HCL-V)和脾边缘区淋巴瘤(SMZL)的鉴别。HCL对2-氯脱氧腺苷(2-CdA)和其他化疗药物具有独特的反应性,这使得这种鉴别至关重要。幸运的是,HCL具有一致的细胞学、组织学、细胞化学和免疫学特征,使得分类可靠且可重复。SMZL和HCL-V的鉴别诊断则不那么直接,这很成问题,因为这两种疾病都很罕见,缺乏基于证据的鉴别标准,而且这两种疾病之间可能存在生物学亲缘关系,它们有许多共同的临床和病理特征。幸运的是,这在临床上并非关键的鉴别点。